Treating drug abuse and addiction in the criminal justice system: Improving public health and safety

JAMA

Volumn 301, Issue 2, 2009, Pages 183-190

  Chandler, Redonna K ^a   Fletcher, Bennett W ^a   Volkow, Nora D ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; NALTREXONE; TOPIRAMATE;

ALCOHOLISM; CLINICAL TRIAL; CRIMINAL BEHAVIOR; CRIMINAL JUSTICE; DRUG ABUSE; DRUG DEPENDENCE; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; NEUROBIOLOGY; OFFENDER; PRIORITY JOURNAL; REVIEW; ADDICTION; ARTICLE; BRAIN; CRIME; HEALTH CARE DELIVERY; MENTAL HEALTH SERVICE; PHYSIOLOGY; PRISON; PUBLIC HEALTH; STATISTICS; UNITED STATES;

BRAIN; CRIME; HEALTH SERVICES ACCESSIBILITY; HUMANS; MENTAL HEALTH SERVICES; PRISONS; PUBLIC HEALTH; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 58249087123     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.976     Document Type: Review

References (81)

1. Glaze LE, Bonczar TP. Probation and Parole in the United States, 2005. Washington, DC: Office of Justice Programs, Bureau of Justice Statistics; 2006. Dept of Justice publication NCJ 215091.
2. Jensen EL, Gerber J, Mosher C. Social consequences of the War on Drugs: the legacy of failed policy. Criminal Justice Policy Review. 2004;15(1):100-121.
3. Karberg JC, James DJ. Substance Dependence, Abuse, and Treatment of Jail Inmates, 2002. Washington, DC: Office of Justice Programs, Bureau of Justice Statistics; 2005. Dept of Justice publication NCJ 209588.
4. Mumola CJ, Karberg JC. Drug Use and Dependence, State and Federal Prisoners, 2004. Washington, DC: Office of Justice Programs, Bureau of Justice Statistics; 2006. Dept of Justice publication NCJ 213530.
5. Weinbaum CM, Sabin KM, Santibanez SS. Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention. AIDS. 2005;19(suppl 3):S41-S46.
6. Abram KM, Teplin LA. Co-occurring disorders among mentally ill jail detainees: implications for public policy. Am Psychol. 1991;46(10):1036-1045.
7. Chandler RK, Peters RH, Field G, Juliano-Bult D. Challenges in implementing evidence-based treatment practices for co-occurring disorders in the criminal justice system. Behav Sci Law. 2004;22(4):431-448.
8. Knight K, Farabee D, eds. Treating Addicted Offenders: A Continuum of Effective Practices. Kingston, NJ: Civic Research Institute; 2004.
9. Langan PA, Levin DJ. Recidivism of Prisoners Released in 1994. Washington, DC: Office of Justice Programs, Bureau of Justice Statistics; 2002. Dept of Justice publication NCJ 193427.
10. Simpler AH, Langhinrichsen-Rohling J. Substance use in prison: how much occurs and is it associated with psychopathology? Addict Res Theory. 2005;13(5):503-511.
11. Field G. Continuity of offender treatment: from the institution to the community. In: Knight K, Farabee D, eds. Treating Addicted Offenders: A Continuum of Effective Practices. Kingston, NJ: Civic Research Institute; 2004:33-1-33-9.
12. Shivy VA, Wu JJ, Moon AE, Mann SC, Holland JG, Eacho C. Ex-offenders reentering the workforce. J Couns Psychol. 2007;54(4):466-473.
13. Volkow ND, Wang GJ, Telang F, et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci. 2006;26(24):6583-6588.
14. Nestler EJ. Review: transcriptional mechanisms of addiction: role of Delta FosB. Philos Trans R Soc Lond B Biol Sci. 2008;363(1507):3245-3255.
15. Grimm JW, Hope BT, Wise RA, Shaham Y. Neuroadaptation: incubation of cocaine craving after withdrawal. Nature. 2001;412(6843):141-142.
16. Inciardi JA, Martin SS, Butzin CA, Hooper RM, Harrison LD. An effective model of prison-based treatment for drug-involved offenders. J Drug Issues. 1997;27(2):261-278.
17. Pearson FS, Lipton DS. A meta-analytic review of the effectiveness of corrections-based treatments for drug abuse. Prison J. 1999;79(4):384-410.
18. Leukefeld CG, Tims F, Farabee D, eds. Treatment of Drug Offenders: Policies and Issues. New York, NY: Springer; 2002.
19. Wormith JS, Althouse R, Simpson M, Reitzel LR, Fagan TJ, Morgan RD. The rehabilitation and reintegration of offenders - the current landscape and some future directions for correctional psychology. Crim Justice Behav. 2007;34(7):879-892.
20. Prendergast ML, Podus D, Chang E, Urada D. The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies. Drug Alcohol Depend. 2002;67(1):53-72.
21. De Leon G. Therapeutic communities: is there an essential model? In: De Leon G, ed. Community as Method: Therapeutic Communities for Special Populations and Special Settings. Westport, CT: Praeger; 1997:3-18.
22. Volkow ND, Li TK. Drugs and alcohol: treating and preventing abuse, addiction and their medical consequences. Pharmacol Ther. 2005;108(1):3-17.
23. Johnson BA, Rosenthal N, Capece JA, et al; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641-1651.
24. Cropsey KL, Villalobos GC, St Clair CL. Pharmacotherapy treatment in substance-dependent correctional populations: a review. Subst Use Misuse. 2005;40(13-14):1983-1999.
25. Humphreys K, Wing S, McCarty D, et al. Self-help organizations for alcohol and drug problems: toward evidence-based practice and policy. J Subst Abuse Treat. 2004;26(3):151-158.
26. Lurigio AJ. Drug treatment availability and effectiveness - studies of the general and criminal justice populations. Crim Justice Behav. 2000;27(4):495-528.
27. Mitchell O, Wilson DB, MacKenzie DL. Does incarceration-based drug treatment reduce recidivism? a meta-analytic synthesis of the research. J Exp Criminol. 2007;3(4):353-375.
28. Peters RH, Murrin MR. Effectiveness of treatment-based drug courts in reducing recidivism. Crim Justice Behav. 2000;27(1):72-96.
29. Butzin CA, O'Connell DJ, Martin SS, Inciardi JA. Effect of drug treatment during work release on new arrests and incarcerations. J Crim Justice. 2006;34(5):557-565.
30. Martin SS, Butzin CA, Saum CA, Inciardi JA. Three-year outcomes of therapeutic community treatment for drug-involved offenders in Delaware: from prison to work release to aftercare. Prison J. 1999;79(3):294-320.
31. Gordon MS, Kinlock TW, Schwartz RP, O'Grady KE. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction. 2008;103(8):1333-1342.
32. Kinlock TW, Gordon MS, Schwartz RP, O'Grady KE. A study of methadone maintenance for male prisoners. Crim Justice Behav. 2008;35(1):34-47.
33. Kinlock TW, Gordon MS, Schwartz RP, O'Grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend. 2007;91(2-3):220-227.
34. Rich JD, Boutwell AE, Shield DC, et al. Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005;82(3):411-419.
35. McCollister KE, French MT, Prendergast ML, Hall E, Sacks S. Long-term cost effectiveness of addiction treatment for criminal offenders. Justice Q. 2004;21(3):659-679.
36. Stephan JJ. State Prison Expenditures, 2001. Washington, DC: Office of Justice Programs, Bureau of Justice Statistics; 2004. Dept of Justice publication NCJ 202949.
37. Rich JD, McKenzie M, Shield DC, et al. Linkage with methadone treatment upon release from incarceration: a promising opportunity. J Addict Dis. 2005;24(3):49-59.
38. Logan TK, Hoyt WH, McCollister KE, French MT, Leukefeld C, Minton L. Economic evaluation of drug court: methodology, results, and policy implications. Eval Program Plann. 2004;27(4):381-396.
39. Daley M, Love CT, Shepard DS, Petersen CB, White KL, Hall FB. Cost-effectiveness of Connecticut's inprison substance abuse treatment. J Offender Rehabil. 2004;39(3):69-92.
40. Flynn PM, Kristiansen PL, Porto JV, Hubbard RL. Costs and benefits of treatment for cocaine addiction in DATOS. Drug Alcohol Depend. 1999;57(2):167-174.
41. Zarkin GA, Dunlap LJ, Hicks KA, Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005;14(11):1133-1150.
42. Taxman FS, Perdoni ML, Harrison LD. Drug treatment services for adult offenders: the state of the state. J Subst Abuse Treat. 2007;32(3):239-254.
43. Hammett TM, Roberts C, Kennedy S. Health-related issues in prisoner reentry. Crime Delinq. 2001;47(3):390-409.
44. Binswanger IA, Stern MF, Deyo RA, et al. Release from prison - a high risk of death for former inmates [published correction appears in N Engl J Med. 2007;356(5):536]. N Engl J Med. 2007;356(2):157-165.
45. Boutwell AE, Allen SA, Rich JD. Opportunities to address the hepatitis C epidemic in the correctional setting. Clin Infect Dis. 2005;40(suppl 5):S367-S372.
46. Zaller N, Thurmond P, Rich JD. Limited spending: an analysis of correctional expenditures on antiretrovirals for HIV-infected prisoners. Public Health Rep. 2007;122(1):49-54.
47. Desai AA, Latta ET, Spaulding A, Rich JD, Flanigan TP. The importance of routine HIV testing in the incarcerated population: the Rhode Island experience. AIDS Educ Prev. 2002;14(5)(suppl B):45-52.
48. Sabin KM, Frey RL Jr, Horsley R, Greby SM. Characteristics and trends of newly identified HIV infections among incarcerated populations: CDC HIV voluntary counseling testing and referral system 1992-1998. J Urban Health. 2001;78(2):241-255.
49. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138(3):187-190.
50. Vallabhaneni S, Macalino GE, Reinert SE, Schwartzapfel B, Wolf FA, Rich JD. Prisoners favour hepatitis C testing and treatment. Epidemiol Infect. 2006;134(2):243-248.
51. Rich JD, Holmes L, Salas C, et al. Successful linkage of medical care and community services for HIV-positive offenders being released from prison. J Urban Health. 2001;78(2):279-289.
52. Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004;38(12):1754-1760.
53. Freudenberg N. Jails, prisons, and the health of urban populations: a review of the impact of the correctional system on community health. J Urban Health. 2001;78(2):214-235.
54. Uhl GR, Grow RW. The burden of complex genetics in brain disorders. Arch Gen Psychiatry. 2004;61(3):223-229.
55. Volkow N, Li TK. The neuroscience of addiction. Nat Neurosci. 2005;8(11):1429-1430.
56. Uhl GR. Molecular genetic underpinnings of human substance abuse vulnerability: likely contributions to understanding addiction as a mnemonic process. Neuropharmacology. 2004;47(suppl 1):140-147.
57. Volkow ND, Fowler JS, Wang GJ. The addicted human brain: insights from imaging studies. J Clin Invest. 2003;111(10):1444-1451.
58. Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the "dark side" of drug addiction. Nat Neurosci. 2005;8(11):1442-1444.
59. Naqvi NH, Rudrauf D, Damasio H, Bechara A. Damage to the insula disrupts addiction to cigarette smoking. Science. 2007;315(5811):531-534.
60. Hester R, Garavan H. Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity. J Neurosci. 2004;24(49):11017-11022.
61. Fellows LK. The role of orbitofrontal cortex in decision making: a component process account. Ann N Y Acad Sci. 2007;1121:421-430.
62. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162(8):1403-1413.
63. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci. 2005;8(11):1481-1489.
64. Gray MA, Critchley HD. Interoceptive basis to craving. Neuron. 2007;54(2):183-186.
65. Kosten TR, Markou A, Koob GF. Depression and stimulant dependence: neurobiology and pharmacotherapy. J Nerv Ment Dis. 1998;186(12):737-745.
66. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997;278(5335):52-58.
67. Winstanley CA. The orbitofrontal cortex, impulsivity, and addiction: probing orbitofrontal dysfunction at the neural, neurochemical, and molecular level. Ann N Y Acad Sci. 2007;1121:639-655.
68. Yücel M, Lubman DI, Solowij N, Brewer WJ. Understanding drug addiction: a neuropsychological perspective. Aust N Z J Psychiatry. 2007;41(12):957-968.
69. Bickel WK, Miller ML, Yi R, Kowal BP, Lindquist DM, Pitcock JA. Behavioral and neuroeconomics of drug addiction: competing neural systems and temporal discounting processes. Drug Alcohol Depend. 2007;90(suppl 1):S85-S91.
70. Madden GJ, Petry NM, Badger GJ, Bickel WK. Impulsive and self-control choices in opioid-dependent patients and non-drug-using control participants: drug and monetary rewards. Exp Clin Psychopharmacol. 1997;5(3):256-262.
71. Shaham Y, Hope BT. The role of neuroadaptations in relapse to drug seeking. Nat Neurosci. 2005;8(11):1437-1439.
72. Baler RD, Volkow ND. Drug addiction: the neurobiology of disrupted self-control. Trends Mol Med. 2006;12(12):559-566.
73. Ersche KD, Sahakian BJ. The neuropsychology of amphetamine and opiate dependence: implications for treatment. Neuropsychol Rev. 2007;17(3):317-336.
74. Kosten TR. Addiction as a brain disease. Am J Psychiatry. 1998;155(6):711-713.
75. Fletcher BW, Chandler RK. Principles of Drug Abuse Treatment for Criminal Justice Populations. Washington, DC: National Institute on Drug Abuse; 2006. NIH publication 06-5316.
76. Wilson DB, Bouffard LA, Mackenzie DL. A quantitative review of structured, group-oriented, cognitive-behavioral programs for offenders. Crim Justice Behav. 2005;32(2):172-204.
77. Gostin LO. Biomedical research involving prisoners: ethical values and legal regulation. JAMA. 2007;297(7):737-740.
78. Wexler HK, Fletcher BW. National Criminal Justice Drug Abuse Treatment Studies (CJ-DATS) overview. Prison J. 2007;87(1):9-24.
79. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl). 2002;159(4):351-360.
80. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210-218.
81. Dackis C, O'Brien C. Neurobiology of addiction: treatment and public policy ramifications. Nat Neurosci. 2005;8(11):1431-1436.